S E Langabeer1, F Ni Ainle, E Conneally, M Lawler. 1. Cancer Molecular Diagnostics, Central Pathology Laboratory, St. James's Hospital, Dublin 8, Ireland. slangabeer@stjames.ie
Abstract
BACKGROUND: The chronic myeloproliferative disorders (MPD) are clonal haemopoietic stem cell disorders. AIMS: The incidence of JAK2 V617F mutation was sought in a population of patients with MPD. METHODS: The JAK2 V617 mutation status was determined in 79 patients with known MPD and 59 patients with features suggestive of MPD. RESULTS: The mutation was found in patients with polycythaemia vera, essential thrombocythaemia, idiopathic myelofibrosis and in patients with other chronic myeloproliferative disorders. Eight JAK2 V617F positive cases were identified amongst those patients with features suggestive of MPD. CONCLUSIONS: The incidence of the JAK2 V617F mutation in MPD patients is similar to that reported by other groups. The assay confirmed and refined the diagnosis of several patients with features indicative of MPD. We suggest screening for this mutation in all patients with known and suspected MPD as identification is valuable in classification and is a potential target for signal transduction therapy.
BACKGROUND: The chronic myeloproliferative disorders (MPD) are clonal haemopoietic stem cell disorders. AIMS: The incidence of JAK2 V617F mutation was sought in a population of patients with MPD. METHODS: The JAK2 V617 mutation status was determined in 79 patients with known MPD and 59 patients with features suggestive of MPD. RESULTS: The mutation was found in patients with polycythaemia vera, essential thrombocythaemia, idiopathic myelofibrosis and in patients with other chronic myeloproliferative disorders. Eight JAK2 V617F positive cases were identified amongst those patients with features suggestive of MPD. CONCLUSIONS: The incidence of the JAK2 V617F mutation in MPD patients is similar to that reported by other groups. The assay confirmed and refined the diagnosis of several patients with features indicative of MPD. We suggest screening for this mutation in all patients with known and suspected MPD as identification is valuable in classification and is a potential target for signal transduction therapy.
Authors: Donald P Mc Lornan; Melanie J Percy; Amy V Jones; Nicholas C P Cross; Mary Frances Mc Mullin Journal: Haematologica Date: 2005-12 Impact factor: 9.941
Authors: Ayalew Tefferi; Terra L Lasho; Susan M Schwager; Jacob S Strand; Michelle Elliott; Ruben Mesa; Chin-Yang Li; Martha Wadleigh; Stephanie J Lee; D Gary Gilliland Journal: Cancer Date: 2006-02-01 Impact factor: 6.860
Authors: Linda M Scott; Peter J Campbell; E Joanna Baxter; Tony Todd; Philip Stephens; Sarah Edkins; Richard Wooster; Michael R Stratton; P Andrew Futreal; Anthony R Green Journal: Blood Date: 2005-10-15 Impact factor: 22.113
Authors: Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland Journal: Cancer Cell Date: 2005-04 Impact factor: 31.743
Authors: Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross Journal: Blood Date: 2005-05-26 Impact factor: 22.113
Authors: Anthony J Bench; Juan Li; Brian J P Huntly; Eric Delabesse; Nasios Fourouclas; Adrienne R Hunt; Panos Deloukas; Anthony R Green Journal: Br J Haematol Date: 2004-12 Impact factor: 6.998
Authors: J J van Dongen; E A Macintyre; J A Gabert; E Delabesse; V Rossi; G Saglio; E Gottardi; A Rambaldi; G Dotti; F Griesinger; A Parreira; P Gameiro; M G Diáz; M Malec; A W Langerak; J F San Miguel; A Biondi Journal: Leukemia Date: 1999-12 Impact factor: 11.528
Authors: Carol Ann Gross-Davis; Karyn Heavner; Arthur L Frank; Craig Newschaffer; Judith Klotz; Regina M Santella; Igor Burstyn Journal: Int J Environ Res Public Health Date: 2015-02-24 Impact factor: 3.390